Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Robust real-world evidence is essential to optimize GLP-1 receptor agonist use and inform policy decisions amid expanding indications and diverse populations.

• Why it matters: Addressing gaps in long-term safety, effectiveness, and economic impact of GLP-1RAs is crucial for improving patient outcomes and ensuring equitable access, especially in underserved groups.
• What they did: A 2025 workshop with experts analyzed current challenges in using real-world data, including data reliability and bias, and discussed strategies to enhance evidence quality for regulatory and clinical decisions.
• The result: Findings highlight the need for high-quality data infrastructure and analytic methods to support value-based coverage policies and optimize GLP-1RA utilization across healthcare systems.